 BioCardia, Inc. Nasdaq: BCDA, a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported that it has accepted and implemented FDA-recommended modifications to the primary endpoint for the CardiAMP Cell Therapy Heart Failure Trial and associated statistical analysis plan. The primary endpoint going forward will be an outcomes composite score based on a three-tiered Finkelstein-Schoenfeld FS hierarchical analysis, an established outcomes design that has been used in other leading heart failure programs. The FS procedure is a ranked analysis that first compares each subject to each other subject for occurrence of first-tier events time to death, in this case and then compares patient outcomes for subsequent tiers. 